MEF2D and osteosarcoma: Correspondingly, high levels of MEF2D expression have been shown to be correlated with a poor patient prognosis, and MEF2D suppression has been shown to decrease the proliferation of hepatocellular carcinoma [17], osteosarcoma [18], and glioma [19].